Eleni Efstathiou, MD, PhD, regarding the PROSPER clinical trial from ASCO GU 2021
Dr. Efstathiou, Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, tells us about the PROSPER clinical trial investigating the role of enzalutamide in non-metastatic castration-resistant prostate cancer (nmCRPC) as presented at ASCO GU 2021 and considers whether PSA is an accurate marker for survival
Eleni Efstathiou, MD, PhD, offers opinion on the ACIS clinical trial
Dr. Efstathiou, Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, explains the design and outcomes of the ACIS study investigating the combination of apalutamide and abiraterone plus prednisone (AAP) versus abiraterone plus prednisone in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC)
Eleni Efstathiou, MD, PhD, elaborates on the role of chemotherapy in mCRPC
Dr. Efstathiou, Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, provides perspective on the role of chemotherapy in metastatic castration-resistant prostate cancer (mCRPC) patients who have failed prior therapies
Eleni Efstathiou, MD, PhD, discusses the prostate-specific membrane antigen (PSMA) lutetium
Dr. Efstathiou, Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the prostate-specific membrane antigen (PSMA) lutetium and outcomes from the VISION clinical trial presented at ASCO GU 2021
Eleni Efstathiou, MD, PhD, considers the role of precision medicine in prostate cancer
Dr. Efstathiou, Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, considers the role of precision medicine in prostate cancer and the clinical significance of the PROFOUND trial from the 2021 Genitourinary Cancers Symposium
Eleni Efstathiou, MD, PhD, regarding the preliminary analysis of belzutifan & cabozantinib in ccRCC
Dr. Efstathiou, Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, regarding the preliminary analysis of combination belzutifan (an oral HIF-2α inhibitor) and cabozantinib in patients with advanced clear cell renal cell carcinoma (ccRCC)
Matthew Galsky, MD, shares a message for patients regarding clinical progress in bladder cancer
Dr. Galsky, Acting Chief, Division of Hematology and Medical Oncology, Mount Sinai Health System, Director of Genitourinary Medical Oncology, Co-Director, Center of Excellence for Bladder Cancer at Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, shares a message for patients regarding clinical progress in bladder cancer as seen at the 2021 Genitourinary Cancers Symposium
Matthew Galsky, MD, on the role of PD-L1 testing in previously untreated, locally advanced or mUC
Dr. Galsky, Acting Chief, Division of Hematology and Medical Oncology, Mount Sinai Health System, Director of Genitourinary Medical Oncology, Co-Director, Center of Excellence for Bladder Cancer at Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, shares perspective on the role of PD-L1 testing in previously untreated, locally advanced or metastatic urothelial carcinoma (mUC) as seen in the Phase III IMvigor130 study presented at ASCO GU 2021
Matthew Galsky, MD, elaborates on outcomes from the CheckMate 274 trial
Dr. Galsky, Acting Chief, Division of Hematology and Medical Oncology, Mount Sinai Health System, Director of Genitourinary Medical Oncology, Co-Director, Center of Excellence for Bladder Cancer at Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, offers opinion on the use of nivolumab as an adjuvant treatment for muscle-invasive urothelial carcinoma as a result of CheckMate 274
Matthew Galsky, MD, regarding Cohort 2 of the EV-201 trial presented at ASCO GU 2021
Dr. Galsky, Acting Chief, Division of Hematology and Medical Oncology, Mount Sinai Health System, Director of Genitourinary Medical Oncology, Co-Director, Center of Excellence for Bladder Cancer at Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, regarding outcomes from Cohort 2 of the EV-201 clinical trial as presented at the 2021 Genitourinary Cancers Symposium
Matthew Galsky, MD, tells us about the design and outcomes of the EV-301 trial from ASCO GU '21
Dr. Galsky, Acting Chief, Division of Hematology and Medical Oncology, Mount Sinai Health System, Director of Genitourinary Medical Oncology, Co-Director, Center of Excellence for Bladder Cancer at Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, tells us about the design and outcomes of the EV-301 clinical study investigating enfortumab vedotin in patients with previously treated advanced urothelial cancer (UC)
Jorge A. Garcia, MD, summarizes the significance of CheckMate 9ER from ASCO GU 2021
Dr. Garcia, Division Chief of Solid Tumor Oncology, George & Edith Richman Distinguished Scientist Chair, University Hospitals Seidman Cancer Center, provides perspective on the CheckMate 9ER clinical trial presented at ASCO GU 2021
Jorge A. Garcia, MD, on the real-world analysis of abiraterone acetate & docetaxel in mHSPC
Dr. Garcia, Division Chief of Solid Tumor Oncology, George & Edith Richman Distinguished Scientist Chair, University Hospitals Seidman Cancer Center, tells us about the real-world analysis of abiraterone acetate and docetaxel in patients with metastatic hormone-sensitive prostate cancer (mHSPC) as presented at the 2021 Genitourinary Cancers Symposium
Jorge A. Garcia, MD, offers opinion on the role of chemotherapy in the treatment of mCRPC
Dr. Garcia, Division Chief of Solid Tumor Oncology, George & Edith Richman Distinguished Scientist Chair, University Hospitals Seidman Cancer Center, offers opinion on the role of chemotherapy in the treatment of metastatic castration-resistant prostate cancer (mCRPC) that has failed prior therapies
Jorge A. Garcia, MD, elaborates on the role of PARP inhibitors in the treatment of mCRPC
Dr. Garcia, Division Chief of Solid Tumor Oncology, George & Edith Richman Distinguished Scientist Chair, University Hospitals Seidman Cancer Center, elaborates on the role of PARP inhibitors in the treatment of metastatic castration-resistant prostate cancer (mCRPC)
Jorge A. Garcia, MD, discusses highlights from the final analysis of the TITAN study
Dr. Garcia, Division Chief of Solid Tumor Oncology, George & Edith Richman Distinguished Scientist Chair, University Hospitals Seidman Cancer Center, discusses highlights from the final analysis of the TITAN study evaluating apalutamide in metastatic hormone-sensitive prostate cancer (mHSPC) patients receiving androgen deprivation therapy (ADT)
Sumanta K. Pal, MD, offers a message to patients regarding clinical progress in kidney cancer
Dr. Pal, Clinical Professor, Department of Medical Oncology & Therapeutics Research, Co-Director, Kidney Cancer Program, City of Hope, offers a message to kidney cancer patients regarding the clinical progress presented at ASCO GU 2021
Sumanta K. Pal, MD, shares thoughts on the TIVO-3 trial from ASCO GU 2021
Dr. Pal, Clinical Professor, Department of Medical Oncology & Therapeutics Research, Co-Director, Kidney Cancer Program, City of Hope, shares thoughts on the TIVO-3 trial investigating tivozanib in the treatment of renal cell carcinoma (RCC) as presented at the 2021 Genitourinary Cancers Symposium
Sumanta K. Pal, MD, offers opinion on the treatment of clear cell renal cell carcinoma
Dr. Pal, Clinical Professor, Department of Medical Oncology & Therapeutics Research, Co-Director, Kidney Cancer Program, City of Hope, tells us about the treatment of clear cell renal cell carcinoma (ccRCC) with cabozantinib and belzutifan, a hypoxia-inducible factor (HIF)-2α inhibitor
William K. Oh, MD, considers the role of PARP inhibitors in mCRPC
Dr. Oh, Clinical Professor of Medicine, Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, considers the role of PARP inhibitors in the treatment of metastatic castration-resistant prostate cancer (mCRPC)
Sumanta K. Pal, MD, elaborates on the significance of the CLEAR trial from ASCO GU 2021
Dr. Pal, Clinical Professor, Department of Medical Oncology & Therapeutics Research, Co-Director, Kidney Cancer Program, City of Hope, regarding the significance of the CLEAR trial, a three-arm study designed to compare lenvatinib plus pembrolizumab versus sunitinib and lenvatinib plus everolimus versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC)
William K. Oh, MD, summarizes outcomes from the ACIS study as presented at ASCO GU 2021
Dr. Oh, Clinical Professor of Medicine, Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, provides a summary of the ACIS study evaluating the combination of apalutamide and abiraterone plus prednisone (AAP) versus abiraterone plus prednisone in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC)
Sumanta K. Pal, MD, regarding the quality of life outcomes from CheckMate 9ER
Dr. Pal, Clinical Professor, Department of Medical Oncology & Therapeutics Research, Co-Director, Kidney Cancer Program, City of Hope, regarding the quality of life outcomes from the CheckMate 9ER clinical trial investigating combination nivolumab and cabozantinib in 1st-line renal cell carcinoma (RCC) as presented at ASCO GU 2021
William K. Oh, MD, offers opinion on the final analysis of the TITAN study
Dr. Oh, Clinical Professor of Medicine, Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, considers the final analysis of the TITAN study investigating apalutamide in metastatic hormone-sensitive prostate cancer (mHSPC) patients receiving androgen deprivation therapy (ADT)
Sumanta K. Pal, MD, considers the unmet needs in the treatment of papillary RCC
Dr. Pal, Clinical Professor, Department of Medical Oncology & Therapeutics Research, Co-Director, Kidney Cancer Program, City of Hope, tell us about the unmet needs in the treatment of papillary renal cell carcinoma (RCC) and what makes this disease unique
William K. Oh, MD, offers opinion on the role of chemotherapy in the treatment of mCRPC
Dr. Oh, Clinical Professor of Medicine, Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, offers opinion on the role of chemotherapy in the treatment of metastatic castration-resistant prostate cancer (mCRPC) that has failed prior therapies
Sumanta K. Pal, MD, elaborates on the design and outcomes of the PAPMET trial from ASCO GU 2021
Dr. Pal, Clinical Professor, Department of Medical Oncology & Therapeutics Research, Co-Director, Kidney Cancer Program, City of Hope, shares the design and outcomes of the PAPMET clinical trial investigating cabozantinib in patients with metastatic papillary renal cell carcinoma (RCC) as presented at the 2021 Genitourinary Cancers Symposium
William K. Oh, MD, on the real-world analysis of abiraterone & docetaxel in mHSPC
Dr. Oh, Clinical Professor of Medicine, Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, discusses the real-world analysis of abiraterone acetate and docetaxel in patients with metastatic hormone-sensitive prostate cancer (mHSPC) as presented at the 2021 Genitourinary Cancers Symposium
Robert J. Motzer, MD, elaborates on key findings from the Phase III CLEAR trial
Dr. Motzer, Kidney Cancer Section Head, Genitourinary Oncology Service, Jack and Dorothy Byrne Chair in Clinical Oncology, Memorial Sloan Kettering Cancer Center, elaborates on key findings from the Phase III CLEAR trial, a three-arm study designed to compare lenvatinib plus pembrolizumab versus sunitinib and lenvatinib plus everolimus versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC)
Robert J. Motzer, MD, offers opinion on whether findings from the CLEAR trial are practice-changing
Dr. Motzer, Kidney Cancer Section Head, Genitourinary Oncology Service, Jack and Dorothy Byrne Chair in Clinical Oncology, Memorial Sloan Kettering Cancer Center, offers opinion on whether findings from the Phase III CLEAR trial will set a new standard of care in advanced clear cell renal cell carcinoma (RCC)
Robert J. Motzer, MD, discusses the side effect profiles of the combinations in the CLEAR trial
Dr. Motzer, Kidney Cancer Section Head, Genitourinary Oncology Service, Jack and Dorothy Byrne Chair in Clinical Oncology, Memorial Sloan Kettering Cancer Center, discusses the side effect profiles of the various combinations studied in the CLEAR trial
Robert J. Motzer, MD, speculates on the future role of combination therapy in advanced ccRCC
Dr. Motzer, Kidney Cancer Section Head, Genitourinary Oncology Service, Jack and Dorothy Byrne Chair in Clinical Oncology, Memorial Sloan Kettering Cancer Center, speculates on the future role of combination therapy in advanced clear cell renal cell carcinoma (ccRCC)
Robert J. Motzer, MD, considers the issue of drug resistance in treating advanced ccRCC
Dr. Motzer, Kidney Cancer Section Head, Genitourinary Oncology Service, Jack and Dorothy Byrne Chair in Clinical Oncology, Memorial Sloan Kettering Cancer Center, considers the issue of drug resistance in treating advanced clear cell renal cell carcinoma (ccRCC)
David A. Braun, MD, PhD, regarding the follow-up trial investigating MK-6482 in ccRCC
Dr. Braun, Physician, Dana-Farber Cancer Institute, Instructor, Harvard Medical School, regarding the Phase I/II follow-up trial investigating single agent MK-6482 [an hypoxia-inducible factor-2 alpha (HIF-2α)] in advanced clear cell renal cell carcinoma (ccRCC)
Jeanny B. Aragon-Ching, MD, FACP, offers opinion on the role of chemotherapy in mCRPC
Dr. Aragon-Ching, Clinical Program Director of Genitourinary Cancers, Inova Schar Cancer Institute/ Inova Fairfax Hospital, Associate Professor of Medicine, University of Virginia, offers opinion on the role of chemotherapy in metastatic castration-resistant prostate cancer (mCRPC) patients who have failed prior therapies
David A. Braun, MD, PhD, discusses the preliminary analysis of belzutifan + cabozantinib in ccRCC
Dr. Braun, Physician, Dana-Farber Cancer Institute, Instructor, Harvard Medical School, discusses the preliminary analysis of the Phase II trial investigating the combination of the oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor belzutifan with cabozantinib in patients with advanced clear cell renal cell carcinoma (ccRCC)
Jeanny B. Aragon-Ching, MD, FACP, elaborates on the IMvigor130 trial
Dr. Aragon-Ching, Clinical Program Director of Genitourinary Cancers, Inova Schar Cancer Institute/ Inova Fairfax Hospital, Associate Professor of Medicine, University of Virginia, tells us about the role of PD-L1 testing in previously untreated locally advanced or metastatic urothelial carcinoma (mUC) as seen in the Phase III IMvigor130 trial presented at the 2021 Genitourinary Cancers Symposium
Jeanny B. Aragon-Ching, MD, FACP, provides perspective on CheckMate-274
Dr. Aragon-Ching, Clinical Program Director of Genitourinary Cancers, Inova Schar Cancer Institute/ Inova Fairfax Hospital, Associate Professor of Medicine, University of Virginia, provides perspective on the results of the CheckMate-274 trial presented at ASCO GU 2021
Jeanny B. Aragon-Ching, MD, FACP, elaborates on the EV-201 clinical trial
Dr. Aragon-Ching, Clinical Program Director of Genitourinary Cancers, Inova Schar Cancer Institute/ Inova Fairfax Hospital, Associate Professor of Medicine, University of Virginia, tells us about cohort 2 of the EV-201 clinical trial investigating patients with previously treated advanced urothelial cancer (UC) who were ineligible for cisplatin chemotherapy treated with enfortumab vedotin
Jeanny B. Aragon-Ching, MD, FACP, shares the design and outcomes of the EV-301 clinical trial
Dr. Aragon-Ching, Clinical Program Director of Genitourinary Cancers, Inova Schar Cancer Institute/ Inova Fairfax Hospital, Associate Professor of Medicine, University of Virginia, shares the design and outcomes of the EV-301 clinical trial investigating enfortumab vedotin in patients with previously treated advanced urothelial cancer (UC) presented at the 2021 Genitourinary Cancers Symposium
Jeanny B. Aragon-Ching, MD, FACP, regarding the CheckMate-9ER trial presented at GU 2021
Dr. Aragon-Ching, Clinical Program Director of Genitourinary Cancers, Inova Schar Cancer Institute/ Inova Fairfax Hospital, Associate Professor of Medicine, University of Virginia, discusses outcomes from the CheckMate-9ER clinical trial investigating combination nivolumab and cabometyx in 1st-line renal cell carcinoma (RCC) as presented at ASCO GU 2021
Tanya Dorff, MD, on how checkpoint inhibitors are being incorporated into mCRPC treatment algorithms
Dr. Dorff, Medical Oncologist, Associate Clinical Professor, Department of Medical Oncology & Therapeutics Research, Head of the Genitourinary Cancers Program, City of Hope, provides an update on how checkpoint inhibitors are being incorporated into treatment algorithms for metastatic castration-resistant prostate cancer (mCRPC)
Daniel M. Geynisman, MD, on how real-world analysis influences clinical decision-making
Dr. Geynisman, Associate Professor, Department of Hematology/Oncology, Fox Chase Cancer Center, explains the significance of real-world analysis and the impact on clinical decision-making
Tanya Dorff, MD, regarding the role of CAR-T cell therapy in the management of PSCA+ mCRPC
Dr. Dorff, Medical Oncologist, Associate Clinical Professor, Department of Medical Oncology & Therapeutics Research, Head of the Genitourinary Cancers Program, City of Hope, regarding the role of CAR-T cell therapy in the management of patients with PSCA+ metastatic castration-resistant prostate cancer (mCRPC)
Elisabeth Heath, MD, FACP, explains the design and outcomes of the ACIS study from ASCO GU 2021
Dr. Heath, Chair, Genitourinary Oncology Multidisciplinary Team, Director, Prostate Cancer Research, Barbara Ann Karmanos Cancer Institute, Professor of Oncology, Wayne State University, explains the design and outcomes of the ACIS study evaluating the combination of apalutamide and abiraterone plus prednisone versus abiraterone plus prednisone in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC)
Daniel M. Geynisman, MD, on the real-world analysis of abiraterone acetate & docetaxel in mHSPC
Dr. Geynisman, Associate Professor, Department of Hematology/Oncology, Fox Chase Cancer Center, regarding the real-world analysis of abiraterone acetate (ABI) and docetaxel (DOC) in men with metastatic hormone-sensitive prostate cancer (mHSPC)
Tanya Dorff, MD, on the role of chemotherapy in mCRPC patients who have failed prior therapies
Dr. Dorff, Medical Oncologist, Associate Clinical Professor, Department of Medical Oncology & Therapeutics Research, Head of the Genitourinary Cancers Program, City of Hope, considers the role of chemotherapy in metastatic castration-resistant prostate cancer (mCRPC) that has failed prior therapies
Elisabeth Heath, MD, FACP, provides opinion on PSA screening in prostate cancer
Dr. Heath, Chair, Genitourinary Oncology Multidisciplinary Team, Director, Prostate Cancer Research, Barbara Ann Karmanos Cancer Institute, Professor of Oncology, Wayne State University, shares thoughts on PSA screening in prostate cancer
Daniel M. Geynisman, MD, considers implications for patients as a result of the RETAIN BLADDER trial
Dr. Geynisman, Associate Professor, Department of Hematology/Oncology, Fox Chase Cancer Center, considers the clinical implications for patients as a result of the RETAIN BLADDER trial
Tanya Dorff, MD, explains the design and outcomes of the ACIS clinical trial
Dr. Dorff, Medical Oncologist, Associate Clinical Professor, Department of Medical Oncology & Therapeutics Research, Head of the Genitourinary Cancers Program, City of Hope, explains the design and outcomes of the ACIS study evaluating the combination of apalutamide and abiraterone plus prednisone versus abiraterone plus prednisone in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC)
Elisabeth Heath, MD, FACP, offers perspective on the KEYNOTE-365 clinical study
Dr. Heath, Chair, Genitourinary Oncology Multidisciplinary Team, Director, Prostate Cancer Research, Barbara Ann Karmanos Cancer Institute, Professor of Oncology, Wayne State University, offers perspective on the KEYNOTE-365 clinical study investigating pembrolizumab plus chemotherapy in pretreated patients with metastatic castration-resistant prostate cancer (mCRPC)
Daniel M. Geynisman, MD, explains the risk-adapted approach used in the RETAIN BLADDER trial
Dr. Geynisman, Associate Professor, Department of Hematology/Oncology, Fox Chase Cancer Center, explains the significance of the risk-adapted approach used in the RETAIN BLADDER clinical trial
Tanya Dorff, MD, offers impressions of the updated TITAN clinical trial from ASCO GU 2021
Dr. Dorff, Medical Oncologist, Associate Clinical Professor, Department of Medical Oncology & Therapeutics Research, Head of the Genitourinary Cancers Program, City of Hope, offers impressions of the updated TITAN study, investigating apalutamide in patients with metastatic castration-sensitive prostate cancer (mCSPC) receiving ADT presented at the 2021 Genitourinary Cancers Symposium
Elisabeth Heath, MD, FACP, shares updated results of the TITAN clinical trial from ASCO GU 2021
Dr. Heath, Chair, Genitourinary Oncology Multidisciplinary Team, Director, Prostate Cancer Research, Barbara Ann Karmanos Cancer Institute, Professor of Oncology, Wayne State University, tells us about the updated results of the TITAN clinical trial investigating apalutamide in patients with metastatic castration-sensitive prostate cancer (mCSPC) receiving ADT
Daniel M. Geynisman, MD, provides an overview of the RETAIN BLADDER presented at ASCO GU 2021
Dr. Geynisman, Associate Professor, Department of Hematology/Oncology , Fox Chase Cancer Center, discusses some of the key interim results from the RETAIN BLADDER trial presented at the 2021 Genitourinary Cancers Symposium
Thomas Powles, MD, PhD, FCRP, offers opinion on whether the results of EV-301 are practice-changing
Dr. Powles, Professor of Genitourinary Oncology, Director, Barts Cancer Centre, Queen Mary University of London, offers opinion on whether the results of the Phase III clinical study investigating enfortumab vedotin (EV) in locally advanced or metastatic urothelial carcinoma are practice-changing
Thomas Powles, MD, PhD, FCRP, regarding the EV-301 Phase III clinical study from ASCO GU 2021
Dr. Powles, Professor of Genitourinary Oncology, Director, Barts Cancer Centre, Queen Mary University of London, shares the design and outcomes of the EV-301 Phase III clinical study investigating enfortumab vedotin (EV) in locally advanced or metastatic urothelial carcinoma (UC) previously treated with platinum-based chemotherapy and a PD-L1 inhibitor
Kim N. Chi, MD, speculates on the future role of apalutamide in the treatment of prostate cancer
Dr. Chi, Medical Oncologist, BC Cancer, Vancouver Prostate Centre, speculates on the future role of apalutamide in the treatment of prostate cancer
Thomas Powles, MD, PhD, FCRP, tell us about the novel antibody-drug conjugate enfortumab vedotin
Dr. Powles, Professor of Genitourinary Oncology, Director, Barts Cancer Centre, Queen Mary University of London, tell us about the novel antibody-drug conjugate enfortumab vedotin (EV) and whether this compound has promise in the management of locally advanced or metastatic urothelial carcinoma (UC)
Kim N. Chi, MD, outlines the safety profile of apalutamide
Dr. Chi, Medical Oncologist, BC Cancer, Vancouver Prostate Centre, describes the safety profile for apalutamide and the health-related quality of life seen in the Phase III TITAN study evaluating apalutamide in metastatic-sensitive prostate cancer patients receiving androgen deprivation therapy (ADT)
Thomas Powles, MD, PhD, FCRP, on the impact of I-O in the management of metastatic UC
Dr. Powles, Professor of Genitourinary Oncology, Director, Barts Cancer Centre, Queen Mary University of London, elaborates on the impact of immuno‑oncology (I-O) in the management of locally advanced or metastatic urothelial carcinoma (UC) and how physicians can manage these patients if/when they progress after receiving I-O or chemotherapy
Kim N. Chi, MD, on what findings from the Phase III TITAN study mean for patients
Dr. Chi, Medical Oncologist, BC Cancer, Vancouver Prostate Centre, explains what the final analysis of the Phase III TITAN study means for patients with metastatic-sensitive prostate cancer
Arlene Siefker-Radtke, MD, regarding the EV-201 Cohort 2 study & clinical implications for patients
Dr. Siefker-Radtke, Professor, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, regarding the EV-201 Cohort 2 study and the clinical implications for patients who cannot tolerate chemotherapy
Kim N. Chi, MD, considers the impact of the crossover design in the analysis of the TITAN study
Dr. Chi, Medical Oncologist, BC Cancer, Vancouver Prostate Centre, considers the impact of the crossover design in the final analysis and how it impacted the overall survival benefit in the Phase III TITAN study evaluating apalutamide in metastatic-sensitive prostate cancer patients receiving androgen deprivation therapy (ADT)
Arlene Siefker-Radtke, MD, discusses key takeaways from the EV-301 study in urothelial cancer
Dr. Siefker-Radtke, Professor, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses some of the most important takeaways from the EV-301 study of enfortumab vedotin (EV) in the treatment of urothelial cancer (UC) as presented at the 2021 Genitourinary Cancers Symposium
Kim N. Chi, MD, regarding key highlights from the final analysis of the Phase III TITAN study
Dr. Chi, Medical Oncologist, BC Cancer, Vancouver Prostate Centre, regarding key clinical highlights from the final analysis of the Phase III TITAN study evaluating apalutamide in metastatic-sensitive prostate cancer patients receiving androgen deprivation therapy (ADT)
Arlene Siefker-Radtke, MD, on the management of treatment-emergent AEs & the use of FGFR inhibitors
Dr. Siefker-Radtke, Professor, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the management of treatment-emergent adverse events (AEs) with use of fibroblast growth factor receptor (FGFR) inhibitors
David Braun, MD, PhD, shares how the treatment of ccRCC in the refractory setting is changing
Dr. Braun, Physician, Dana-Farber Cancer Institute, Instructor, Harvard Medical School, shares how the treatment of clear cell renal cell carcinoma (ccRCC) in the refractory setting is changing
Arlene Siefker-Radtke, MD, discusses some of the antibody drug conjugates currently in development
Dr. Siefker-Radtke, Professor, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses some of the antibody drug conjugates (ADCs) in the pipeline and targets beyond Nectin-4
David Braun, MD, PhD, considers the evolving treatment landscape of 1st line ccRCC
Dr. Braun, Physician, Dana-Farber Cancer Institute, Instructor, Harvard Medical School, considers the evolving treatment landscape of 1st line clear cell renal cell carcinoma (ccRCC)
Arlene Siefker-Radtke, MD, speculates on the role of antibody drug conjugates in the treatment of UC
Dr. Siefker-Radtke, Professor, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, speculates on the role of antibody drug conjugates (ADCs) in the treatment of urothelial carcinoma (UC)
David Braun, MD, PhD, offers opinion on the role of HIF-2α inhibitors in ccRCC
Dr. Braun, Physician, Dana-Farber Cancer Institute, Instructor, Harvard Medical School, offers opinion on the role of hypoxia-inducible factor-2 alpha (HIF-2α) inhibitors in clear cell renal cell carcinoma (ccRCC)
Eleni Efstathiou, MD, PhD, provides perspective on the IPATential150 study in mCRPC
Dr. Efstathiou, Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, provides perspective on the IPATential150 study in metastatic castration-resistant prostate cancer (mCRPC) presented at the 2020 ESMO Virtual Congress ESMO20
Eleni Efstathiou, MD, PhD, on whether genetic mutation data impacts the treatment of prostate cancer
Dr. Efstathiou, Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the impact of recent clinical trials focused on genetic mutations and whether they are impacting the way we treat prostate cancer patients
Eleni Efstathiou, MD, PhD, on the practice-changing potential of the PROfound study from ESMO 2020
Dr. Efstathiou, Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, tells us about the outcomes of the PROfound study and whether medical oncologists should consider olaparib in the management of their metastatic castration-resistant prostate cancer (mCRPC) patients
Matthew Galsky, MD, on how studies focused on genetic mutations impact prostate cancer treatment
Dr. Galsky, Professor of Medicine, Director of Genitourinary Medical Oncology, Director of the Novel Therapeutics Unit, and Co-Director, Center of Excellence for Bladder Cancer, The Tisch Cancer Institute and Icahn School of Medicine at Mount Sinai, explains how recent clinical studies focused on genetic mutations are influencing the way advanced prostate cancer is treated
Arun Azad, MBBS, PhD, FRACP, on the evolving treatment landscape of advanced prostate cancer
Dr. Azad, Associate Professor, Medical Oncologist, Peter MacCallum Cancer Centre, Victoria, Australia, speculates on how recent clinical trials focused on genetic mutations impact the way advanced prostate cancer is treated
Matthew Galsky, MD, discusses the practice-changing potential of the PROfound study from ESMO 2020
Dr. Galsky, Professor of Medicine, Director of Genitourinary Medical Oncology, Director of the Novel Therapeutics Unit, and Co-Director, Center of Excellence for Bladder Cancer, The Tisch Cancer Institute and Icahn School of Medicine at Mount Sinai, tells us about the outcomes of the PROfound study whether medical oncologists should olaparib in the management of their metastatic castration-resistant prostate cancer (mCRPC) patients
Arun Azad, MBBS, PhD, FRACP, considers how recent clinical trials influence the treatment of mCRPC
Dr. Azad, Associate Professor, Medical Oncologist, Peter MacCallum Cancer Centre, Victoria, Australia, considers how treatment algorithms for metastatic castration-resistant prostate cancer (mCRPC) have changed as a result of recent clinical trial outcomes (i.e. PROfound and CARD)
Arun Azad, MBBS, PhD, FRACP, tells us about the outcomes of the PROfound study presented at ESMO '20
Dr. Azad, Associate Professor, Medical Oncologist, Peter MacCallum Cancer Centre, Victoria, Australia, tells us about the outcomes of the PROfound study and considers whether medical oncologists should include olaparib in the management of their metastatic castration-resistant prostate cancer (mCRPC) patients
Arun Azad, MBBS, PhD, FRACP, shares impressions of the post-hoc analysis of the ARCHES study
Dr. Azad, Associate Professor, Medical Oncologist, Peter MacCallum Cancer Centre, Victoria, Australia, shares impressions of the post-hoc analysis of the ARCHES study investigating the role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC) presented at the 2020 ESMO Virtual Congress
Nicholas James, MD, PhD, offers a summary of the STAMPEDE study to date
Dr. James, Professor of Clinical Oncology, The Institute of Cancer Research, London, tells us about the results of the STAMPEDE study to date and provides an update on Arm G presented at the 2020 ESMO Virtual Congress
Nicholas James, MD, PhD, analyzes the duration of response in Arm G of the STAMPEDE clinical trial
Dr. James, Professor of Clinical Oncology, The Institute of Cancer Research, London, analyzes the duration of response in Arm G of the STAMPEDE clinical trial and shares thoughts on the quality of life (QoL) endpoint in this group of patients
Petros Grivas, MD, PhD, summarizes the clinical progress made in prostate cancer from ESMO 2020
Dr. Grivas, Physician, Seattle Cancer Care Alliance, Associate Professor, Division of Medical Oncology, University of Washington School of Medicine, Clinical Director, Genitourinary Cancers Program, UW Medicine, Associate Professor, Clinical Research Division, Fred Hutchinson Cancer Research Center, summarizes the clinical progress made at the 2020 ESMO Virtual Congress in prostate cancer as seen in three major studies
Maha Hussain, MD, provides perspective on the Phase III PROfound study presented at ESMO 2020
Dr. Hussain, Genevieve E. Teuton Professor of Medicine, Professor of Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern Medicine, provides perspective on the Phase III PROfound study presented at the 2020 ESMO Virtual Congress and whether medical oncologists should consider olaparib in the management of their metastatic castration-resistant prostate cancer (mCRPC) patients
Maha Hussain, MD, shares the design of the Phase III PROfound study in mCRPC
Dr. Hussain, Genevieve E. Teuton Professor of Medicine, Professor of Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern Medicine, shares the design of the Phase III PROfound study investigating the use of olaparib versus enzalutamide or abiraterone in metastatic castration-resistant prostate cancer (mCRPC) presented at the 2020 ESMO Virtual Congress
Maha Hussain, MD, considers the role of homologous recombination repair in the management of mCRPC
Dr. Hussain, Genevieve E. Teuton Professor of Medicine, Professor of Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern Medicine, considers the role of homologous recombination repair (HRR) in the management of metastatic castration-resistant prostate cancer (mCRPC)
Maha Hussain, MD, regarding the evolving treatment landscape of mCRPC
Dr. Hussain, Genevieve E. Teuton Professor of Medicine, Professor of Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern Medicine, tells us about the current landscape for the treatment of metastatic castration resistant prostate cancer (mCRPC)
Rana McKay, MD, shares results of the randomized Phase 2 study investigating luPSMA vs cabazitaxel
Dr. McKay, Assistant Professor of Medicine, UCSD, shares the results of the randomized Phase 2 study investigating luPSMA vs cabazitaxel in men with metastatic prostate cancer
Rana McKay, MD, elaborates on the advent of hormonal agents for patients with metastatic prostate cancer
Dr. McKay, Assistant Professor of Medicine, UCSD, elaborates on how the advent of hormonal agents for patients with metastatic prostate cancer are changing the paradigm in treatment
Derek Raghavan, MD, discusses the efficacy and utility of the new GNRH antagonist, Reugolix
Dr. Raghavan, President, Levine Cancer Institute at Atrium Health, discusses the efficacy and utility of the new GNRH antagonist, Reugolix, in prostate cancer
Derek Raghavan, MD, explains toxicities and factors determining GNRH-based therapies selection
Dr. Raghavan, President, Levine Cancer Institute at Atrium Health, explains the toxicities and factors that determine selection of GNRH-based therapies in prostate cancer
Derek Raghavan, MD, provides a general overview of prostate cancer therapies
Dr. Raghavan, President, Levine Cancer Institute at Atrium Health, provides a general overview of prostate cancer therapies
Nicholas Vogelzang, MD, FASCO, FACP, describes the role of PARP inhibitors advanced prostate cancer
Dr. Vogelzang, Co-Chair GU Oncology for SWOG, Comprehensive Cancer Centers of Nevada, describes the role of PARP inhibitors in treating advanced prostate cancer
Nicholas Vogelzang, MD, FASCO, FACP, provides updates on PSMA radioligands for PET imaging
Dr. Vogelzang, Dr. Vogelzang, Co-Chair GU Oncology for SWOG, Comprehensive Cancer Centers of Nevada, provides updates on PSMA radioligands for PET imaging in prostate cancer
Nicholas Vogelzang, MD, discusses re-emergence of dose reduced cabozantinib + alezotuzumab in advanced prostate cancer
Dr. Vogelzang, Co-Chair GU Oncology for SWOG, Comprehensive Cancer Centers of Nevada, discusses the re-emergence of dose reduced cabozantinib combined with alezotuzumab in advanced prostate cancer
Nicholas Vogelzang, MD, provides thoughts on the role of radium 223 in management of advanced metastatic prostate cancer
Dr. Vogelzang, Co-Chair GU Oncology for SWOG, Comprehensive Cancer Centers of Nevada, provides thoughts on the role of Xofigo (radium 223) in the management of advanced metastatic prostate cancer
Nicholas Vogelzang, MD, explains how cabazitaxel should be used in various lines of treatment in metastatic prostate cancer
Dr. Vogelzang, Co-Chair GU Oncology for SWOG, Comprehensive Cancer Centers of Nevada, explains how cabazitaxel should be used in various lines of treatment in metastatic prostate cancer
Nicholas Vogelzang, MD, FASCO, FACP, considers the dosing effects of cabazitaxel in clinical studies
Dr. Vogelzang, Co-Chair GU Oncology for SWOG, Comprehensive Cancer Centers of Nevada, considers dosing effects of cabazitaxel in clinical studies, including the CARD study
Nicholas Vogelzang, MD, FASCO, FACP, on CARD study impressions comparing novel hormonal therapy to cabazitaxel
Dr. Vogelzang, Co-Chair GU Oncology for SWOG, Comprehensive Cancer Centers of Nevada, shares impressions on the CARD study comparing novel hormonal therapy to cabazitaxel in castration resistant metastatic prostate cancer
Nicholas Vogelzang, MD, FASCO, FACP, updates us on the status of PSMA-linked radiopharmaceuticals
Dr. Vogelzang, Co-Chair GU Oncology for SWOG, Comprehensive Cancer Centers of Nevada, updates us on the status of PSMA-linked radiopharmaceuticals for treating recurrent prostate cancer
Tomasz Beer, MD, FACP, discusses the recently FDA approved relugolix
Dr. Beer, Chief Medical Officer, OSHU Knight Cancer Institute, discusses relugolix, the newly FDA approved oral GNRH antagonist for prostate cancer
Tomasz Beer, MD, FACP, provides preliminary data presented concerning androgen receptor degraders
Dr. Beer, Chief Medical Officer, OSHU Knight Cancer Institute, provides preliminary data as presented at ASCO concerning a new class of androgen receptor degraders
Tomasz Beer, MD, FACP, on how to treat patients who are progressing on androgen receptor inhibitors
Dr. Beer, Chief Medical Officer, OSHU Knight Cancer Institute, on how to treat patients who are progressing on androgen receptor inhibitors
Tomasz Beer, MD, FACP, explains which nmCRPC patients to treat with androgen receptor inhibitors
Dr. Beer, Chief Medical Officer, OSHU Knight Cancer Institute, explains which nonmetastatic castration-resistant prostate cancer (nmCRPC) patients to treat with androgen receptor inhibitors and how to select these patients
Tomasz Beer, MD, FACP, reviews updates concerning androgen receptor inhibitors in nmCRPC
Dr. Beer, Chief Medical Officer, OSHU Knight Cancer Institute, reviews updates concerning androgen receptor inhibitors in nonmetastatic castrate resistant prostate cancer as presented at ASCO20
Scott Tagawa, MD, elaborates on what may account for resistance to PSMA radioligand therapies
Dr. Tagawa, Medical Director of the Genitourinary Oncology Program, Weill Cornell Medicine and NewYork-Presbyterian, elaborates on what may account for resistance to PSMA radioligand therapies
Scott Tagawa, MD, explains how PSMA PET imaging is utilized with PSMA-based therapies
Dr. Tagawa, Medical Director of the Genitourinary Oncology Program, Weill Cornell Medicine and NewYork-Presbyterian, explains how PSMA PET imaging is utilized with PSMA-based therapies
Scott Tagawa, MD, defines the 177Lutethium Beta emitter and the 225Actinium Alpha emitter PMSA-linked therapies
Dr. Tagawa, Medical Director of the Genitourinary Oncology Program, Weill Cornell Medicine and NewYork-Presbyterian, describes differences between and utilizing the development of 177Lutethium Beta emitter PSMA-linked therapy and that of 225Actinium Alpha emitter PSMA-linked therapy as used in the Ph I reported trial
Scott Tagawa, MD, considers next steps in the development of the PSMA-targeted alpha emitter in mCRPC
Dr. Tagawa, Medical Director of the Genitourinary Oncology Program, Weill Cornell Medicine and NewYork-Presbyterian, considers next steps in the development of the PSMA-targeted alpha emitter 25Ac-J591 in men with metastatic castration-resistant prostate cancer (mCRPC)
Scott Tagawa, MD, discusses the results of Phase I dose-escalation study regarding mCRPC
Dr. Tagawa, Medical Director of the Genitourinary Oncology Program at Weill Cornell Medicine and NewYork-Presbyterian, discusses the results of the Phase I dose-escalation study of PSMA-targeted alpha emitter 25Ac-J591 in men with metastatic castration-resistant prostate cancer (mCRPC)
Fred Saad MD, on SPARTAN study highlights for oncologists that do not specialize in prostate cancer
Dr. Saad, Professor and Chairman of Urology, University of Montreal Hospital Center, shares highlights of the SPARTAN study that medical oncologists that do not specialize in prostate cancer should be aware of
Fred Saad, MD, on genetic testing to be conducted in a patient with metastatic prostate cancer
Dr. Saad, Professor and Chairman of Urology, University of Montreal Hospital Center, elaborates on genetic testing to be conducted in a patient with metastatic prostate cancer
Fred Saad, MD, shares impressions of the CARD study investigating cabazitaxel in nmCRPC patients
Dr. Saad, Professor and Chairman of Urology, University of Montreal Hospital Center, shares impressions of the CARD study investigating cabazitaxel in metastatic castration-resistant prostate cancer patients
Fred Saad, MD, details safety concerns when prescribing apalutamide + ADT to nmCRPC patients
Dr. Saad, Professor and Chairman of Urology, University of Montreal Hospital Center, details potential safety concerns when prescribing Erleada (apalutamide) + ADT to non-metastatic castration-resistant prostate cancer patients
Fred Saad, MD, shares the design and outcomes of the SPARTAN study in patients with nmCRPC
Dr. Saad, Professor and Chairman of Urology, University of Montreal Hospital Center, shares design and outcomes of the SPARTAN study comparing Erleada (apalutamide) + ADT to ADT alone in patients with non-metastatic castration-resistant prostate cancer
Follow @OBRTweets